Summit Plc to list on Nasdaq

4th February 2015

AIM-listed Summit plc has filed for a proposed offering of American Depositary Shares on the NASDAQ Global Market in the United States.

Summit Plc

Summit Plc is developing therapies for Duchenne Muscular Dystrophy and C. difficile infection. The proposed US offering is subject to certain resolutions being passed by the shareholders of Summit at a General Meeting that is expected to be held on or around 19 February 2015.

Summit Plc was spun out by Oxford University Innovation in 2003.

See: Oxford Researchers Working on New Drugs to Treat Duchenne Muscular Dystrophy

Visit the Summit Plc website.

 

Press release sign up